News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
378,583 Results
Type
Article (22230)
Company Profile (150)
Press Release (356189)
Multimedia
Podcasts (112)
Webinars (17)
Section
Business (112612)
Career Advice (933)
Deals (19884)
Drug Delivery (114)
Drug Development (53301)
Employer Resources (84)
FDA (8745)
Job Trends (8343)
News (198464)
Policy (18571)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (866)
Accelerated approval (20)
Adcomms (23)
Allergies (85)
Alliances (30086)
ALS (95)
Alzheimer's disease (858)
Antibody-drug conjugate (ADC) (218)
Approvals (8936)
Artificial intelligence (303)
Autoimmune disease (82)
Automation (18)
Bankruptcy (185)
Best Places to Work (6015)
BIOSECURE Act (14)
Biosimilars (173)
Biotechnology (68)
Bladder cancer (85)
Brain cancer (38)
Breast cancer (290)
Cancer (2519)
Cardiovascular disease (247)
Career advice (778)
Career pathing (24)
CAR-T (122)
CDC (15)
Cell therapy (321)
Cervical cancer (12)
Clinical research (46770)
Collaboration (1063)
Company closure (1)
Compensation (379)
Complete response letters (52)
COVID-19 (1228)
CRISPR (55)
C-suite (546)
Cystic fibrosis (89)
Data (3556)
Decentralized trials (2)
Denatured (27)
Depression (84)
Diabetes (266)
Diagnostics (2353)
Digital health (16)
Diversity (10)
Diversity, equity & inclusion (25)
Drug discovery (175)
Drug pricing (200)
Drug shortages (33)
Duchenne muscular dystrophy (139)
Earnings (43557)
Editorial (47)
Employer branding (10)
Employer resources (82)
Events (55097)
Executive appointments (635)
FDA (10463)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (3)
Frontotemporal dementia (6)
Funding (699)
Gene editing (97)
Generative AI (34)
Gene therapy (286)
GLP-1 (833)
Government (2176)
Grass and pollen (4)
Guidances (222)
Healthcare (6872)
HIV (29)
Huntington's disease (25)
IgA nephropathy (60)
Immunology and inflammation (168)
Immuno-oncology (37)
Indications (71)
Infectious disease (1372)
Inflammatory bowel disease (121)
Inflation Reduction Act (12)
Influenza (50)
Intellectual property (142)
Interviews (120)
IPO (8102)
IRA (53)
Job creations (2509)
Job search strategy (686)
JPM (52)
Kidney cancer (10)
Labor market (61)
Layoffs (348)
Leadership (27)
Legal (4348)
Liver cancer (38)
Longevity (9)
Lung cancer (364)
Lymphoma (226)
Machine learning (23)
Management (31)
Manufacturing (547)
MASH (110)
Medical device (3359)
Medtech (3369)
Mergers & acquisitions (12360)
Metabolic disorders (908)
Multiple sclerosis (100)
NASH (20)
Neurodegenerative disease (169)
Neuropsychiatric disorders (72)
Neuroscience (1611)
Neurotech (1)
NextGen: Class of 2026 (2661)
Non-profit (1110)
Now hiring (45)
Obesity (518)
Opinion (235)
Ovarian cancer (68)
Pain (151)
Pancreatic cancer (98)
Parkinson's disease (162)
Partnered (19)
Patents (289)
Patient recruitment (265)
Peanut (21)
People (36081)
Pharmaceutical (77)
Pharmacy benefit managers (33)
Phase 1 (14696)
Phase 2 (19844)
Phase 3 (15808)
Pipeline (3085)
Policy (236)
Postmarket research (1673)
Preclinical (5196)
Press Release (62)
Prostate cancer (141)
Psychedelics (27)
Radiopharmaceuticals (197)
Rare diseases (531)
Real estate (3453)
Recruiting (34)
Regulatory (14648)
Reports (29)
Research institute (921)
Resumes & cover letters (147)
Rett syndrome (6)
RNA editing (12)
RSV (45)
Schizophrenia (124)
Series A (125)
Series B (92)
Service/supplier (7)
Sickle cell disease (65)
Special edition (21)
Spinal muscular atrophy (120)
Sponsored (20)
Startups (2124)
State (2)
Stomach cancer (14)
Supply chain (78)
Tariffs (94)
The Weekly (83)
Vaccines (433)
Venture capital (68)
Weight loss (379)
Women's health (41)
Worklife (9)
Date
Last 7 days (321)
Last 30 days (1146)
Last 365 days (16327)
2026 (1551)
2025 (16588)
2024 (19099)
2023 (21236)
2022 (28977)
2021 (30545)
2020 (28438)
2019 (22533)
2018 (17417)
2017 (18795)
2016 (17720)
2015 (20550)
2014 (16012)
2013 (13617)
2012 (14586)
2011 (14897)
2010 (13673)
Location
Africa (457)
Alabama (42)
Alaska (3)
Arizona (98)
Arkansas (8)
Asia (27988)
Australia (4168)
California (5212)
Canada (1920)
China (777)
Colorado (206)
Connecticut (215)
Delaware (190)
Europe (59614)
Florida (877)
Georgia (154)
Hawaii (2)
Idaho (20)
Illinois (467)
India (51)
Indiana (312)
Iowa (9)
Japan (353)
Kansas (86)
Kentucky (29)
Louisiana (7)
Maine (10)
Maryland (623)
Massachusetts (4088)
Michigan (76)
Minnesota (287)
Mississippi (3)
Missouri (52)
Montana (14)
Nebraska (15)
Nevada (38)
New Hampshire (23)
New Jersey (2006)
New Mexico (21)
New York (1428)
North Carolina (843)
North Dakota (3)
Northern California (2477)
Ohio (134)
Oklahoma (9)
Oregon (24)
Pennsylvania (1136)
Puerto Rico (19)
Rhode Island (27)
South America (652)
South Carolina (13)
Southern California (2151)
Tennessee (66)
Texas (700)
United States (19609)
Utah (104)
Virginia (181)
Washington D.C. (62)
Washington State (414)
West Virginia (1)
Wisconsin (51)
Wyoming (2)
378,583 Results for "obi pharma usa".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC
January 12, 2026
·
5 min read
Press Releases
Dexcel Pharma USA Acquires US Rights to Zubsolv®
January 8, 2026
·
1 min read
Press Releases
OBI Pharma Announces Phase 1/2 Study Initiation for OBI-902, a TROP2 Targeted Antibody-Drug Conjugate Therapy (ADC) in Advanced Solid Tumors
September 2, 2025
·
5 min read
Press Releases
OBI-902 Has Been Granted by US FDA for Orphan Drug Designation for the Treatment of Cholangiocarcinoma
November 18, 2025
·
6 min read
Press Releases
OBI Pharma Enters ADC Collaboration with TegMine Therapeutics utilizing GlycOBI® and TegMiner™ Enabling Technologies
June 6, 2025
·
4 min read
Press Releases
OBI Pharma Announces Poster Presentations at the AACR 2025 Annual Meeting for OBI-992 and OBI-902 Antibody-Drug Conjugates (ADCs), GlycOBI® and ThiOBI® ADC enabling technologies, the OBI-3424 prodrug, and Globo H (GH) science
April 23, 2025
·
12 min read
Press Releases
OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-902, a Trop-2 Targeting ADC
May 1, 2025
·
4 min read
Press Releases
PharmaEssentia USA Announces Appointment of Jeffrey Williams as Independent Director
December 25, 2025
·
2 min read
Drug Development
OBI Pharma Announces Phase 1/2 Study Initiation for OBI-992, a TROP2-Targeted Antibody-Drug Conjugate (ADC) for Cancer TherapyClinical trial to evaluate the safety and efficacy of OBI-992 in advanced solid tumors.
OBI Pharma, a clinical-stage oncology company, announced the initiation of a Phase 1/2 clinical trial of OBI-992, an antibody-drug conjugate targeting TROP2, an antigen overexpressed in multiple tumor types.
June 12, 2024
·
3 min read
Press Releases
Zydus and RK Pharma enter into an exclusive licensing and commercialization agreement for a novel 505(b)(2) product of supportive oncology treatment for the USA market
November 27, 2025
·
3 min read
1 of 37,859
Next
